Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 11OTHER 8NETWORK 3NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11Head & Neck 5Gastrointestinal 5CNS 4Sarcoma 3Other solid neoplasm 3Gynecologic 3Genitourinary 2Endocrine 2Dermatologic 2Breast 2

Conditions

Breast Neoplasms 2Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 80Paclitaxel 53Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Gefitinib × Breast × Clear all
NCT00057941 2014-05-12

Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
148 enrolled 7 charts
Breast

Breast Neoplasms

NCT00024154 2013-01-24

Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
132 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡